Development of an assay to screen for inhibitors of tau phosphorylation by Cdk5

Journal of Biomolecular Screening

Volumn 9, Issue 2, 2004, Pages 122-131

  Ahn, Jae Suk ^a   Musacchio, Andrea ^d   Mapelli, Marina ^d   Ni, Jake ^b   Scinto, Leonard ^c   Stein, Ross ^b   Kosik, Kenneth S ^a   Yeh, Li An ^b,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e The Harvard Center for Neurodegeneration & Repair   (United States)

Author keywords

Alzheimer's disease; Cdk5; HTS; Tau phosphorylation

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYCLIN DEPENDENT KINASE 5 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PHF 1; PROTEIN P25; RECOMBINANT PROTEIN; SERINE; TAU PROTEIN; UNCLASSIFIED DRUG; CDK5 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 5; KINETIN; OLOMOUCINE; PHF 1; PHF-1; PURINE DERIVATIVE;

ARTICLE; COLORIMETRY; CONTROLLED STUDY; DRUG DETERMINATION; ENZYME ACTIVE SITE; ENZYME KINETICS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME MECHANISM; HIGH THROUGHPUT SCREENING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; VALIDATION PROCESS; BINDING SITE; BIOTINYLATION; CELL CULTURE; DRUG ANTAGONISM; ELECTRONICS; ENZYME SPECIFICITY; HUMAN; KINETICS; METABOLISM; PHOSPHORYLATION; PROTEIN BINDING; TIME;

ADENOSINE TRIPHOSPHATE; ANTIBODIES, MONOCLONAL; BINDING SITES; BIOTINYLATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE 5; CYCLIN-DEPENDENT KINASES; HUMANS; KINETICS; KINETIN; MINIATURIZATION; PHOSPHORYLATION; PROTEIN BINDING; PURINES; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; TAU PROTEINS; TIME FACTORS;

EID: 14644434917     PISSN: 10870571     EISSN: None     Source Type: Journal    
DOI: 10.1177/1087057103260594     Document Type: Article

References (40)

1. Tolnay M, Probst A: REVIEW: tau protein pathology in Alzheimer's disease and related disorders. Neuropathol Appl Neurobiol 1999;25:171-187.
2. Kosik KS: Tau: structure and function. In Avila J, Brandt R, Kosik KS (eds): Brain Microtubule Associated Proteins. Amsterdam: Harwood Academic, 1997:43-52.
3. Takahashi S, Saito T, Hisanaga S, Pant HC, Kulkarni AB: Tau phosphorylation by cyclin-dependent kinase 5/p39 during brain development reduces its affinity for microtubules. J Biol Chem 2003;278:10506-10515.
4. Matsuo ES, Shin RW, Billingsley ML, et al: Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron 1994;13:989-1002.
5. Brion JP, Octave JN, Couck AM: Distribution of the phosphorylated microtubule-associated protein tau in developing cortical neurons. Neuroscience 1994;63:895-909.
6. Riederer BM, Binder LI: Differential distribution of tau proteins in developing cat cerebellum. Brain Res Bull 1994;33:155-161.
7. Morishima-Kawashima M, Hasegawa M, Takio K, et al: Proline-directed and non-proline-directed phosphorylation of PHF-tau. J Biol Chem 1995;270:823-829.
8. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT: Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 2002;103:26-35.
9. Scott CW, Spreen RC, Herman JL, et al: Phosphorylation of recombinant tau by cAMP-dependent protein kinase: identification of phosphorylation sites and effect on microtubule assembly. J Biol Chem 1993;268:1166-1173.
10. +2- and calmodulin-dependent phosphorylation of microtubule-associated protein 2 and tau factor, and inhibition of microtubule assembly. J Neurochem 1983;41:1119-1125.
11. Correas I, Diaz-Nido J, Avila J: Microtubule-associated protein tau is phosphorylated by protein kinase C on its tubulin binding domain. J Biol Chem 1992;267:15721-15728.
12. Pierre M, Nunez J: Multisite phosphorylation of tau proteins from rat brain. Biochem Biophys Res Commun 1983;115:212-219.
13. Drews G, Lichtenberg-Kraag B, Doring F, et al: Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J 1992;1:2131-2138.
14. Schneider A, Biernat J, van Bergen M, Mandelkow E, Mandelkow EM: Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 1999;38:3549-3558.
15. Mandelkow EM, Drewes G, Biernat J, et al: Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett 1992;314:315-321.
16. Kobayashi S, Ishiguro K, Omori A, et al: A cdc2-related kinase PSSALRE/cdk5 is homologous with the 30 kDa subunit of tau protein kinase II, a proline-directed protein kinase associated with microtubule. FEBS Lett 1993;335:171-175.
17. Paudel HK, Lew J, AIi Z, Wang JH: Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments. J Biol Chem 1993;268:23512-23518.
18. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH: Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999;402:588-589.
19. Arioka M, Tsukamoto M, Ishiguro K, et al: Tau protein kinase II is involved in the regulation of the normal phosphorylation state of tau protein. J Neurochem 1993;60:461-468.
20. Dhavan R, Tsai LH: A decade of CDK5. Nat Rev Mol Cell Biol 2001;2:749-759.
21. Mandelkow EM, Biernat J, Drewes G, Gustke N, Trinczek B, Mandelkow E: Tau domains, phosphorylation, and interactions with microtubules. Neurobiol Aging 1995;16:355-362.
22. Illenberger S, Zheng-Fischhofer Q, Preuss U, et al: The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease. Mol Biol Cell 1998;9:1495-1512.
23. Evans DB, Rank KB, Bhattacharya K, Thomsen DR, Gurney ME, Sharma SK: Tau phosphorylation at serine 396 and serine 404 by human recombinant tau protein kinase II inhibits tau's ability to promote microtubule assembly. J Biol Chem 2000;275:24977-24983.
24. Greenberg SG, Davies P: A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci USA 1990;87:5827-5831.
25. Otvos L Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM: Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 1994;39:669-673.
26. Knockaert M, Greengard P, Meijer L: Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002;23:417-425.
27. Sielecki TM, Boylan JF, Benfield PA, Trainor GL: Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J Med Chem 2000;43:1-18.
28. Garrett MD, Fattaey A: CDK inhibition and cancer therapy. Curr Opin Genet Dev 1999;9:104-111.
29. Gray N, Detivaud L, Doerig C, Meijer L: ATP-site directed inhibitors of cyclin-dependent kinases. Curr Med Chem 1999;6:859-875.
30. Meijer L, Leclerc S, Leost M: Properties and potential applications of chemical inhibitors of cyclin-dependent kinases. Pharmacol Ther 1999;82:279-284.
31. Leost M, Schultz C, Link A, et al: Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25. Eur J Biochem 2000;267:5983-5994.
32. Mettey Y, Compel M, Thomas V, et al: Aloisines, a new family of CDK/GSK-3 inhibitors: SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem 2003;46:222-236.
33. Kim KS, Kimball D, Cai ZW, et al: Aminothiazole inhibitors of cyclin dependent kinases. US 6,262,096 B1 (July 17, 2001).
34. Lee G, Neve RL, Kosik KS: The microtubule binding domain of tau protein. Neuron 1989;2:1615-1624.
35. Tarricone C, Dhavan R, Peng J, Areces LB, Tsai LH, Musacchio A: Structure and regulation of the CDK5-p25(nck5a) complex. Mol Cell 2001;8:657-669.
36. 205 of human tau. J Biol Chem 2002;277:44525-44530.
37. Vesely J, Havlicek L, Strnad M, et al: Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 1994;224:771-786.
38. Lipinski CA, Lombarde F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26.
39. Fischer PM: Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors. Curr Opin Drug Discov Dev 2001;4:623-634.
40. Meijer L, Thunnissen AM, White AW, et al: Inhibition of cyclin-dependent kinase, GSK-3β and casein kinase 1 by hymenialdisine, a marine sponge constituent. Chem Biol 2000;7:51-63.